A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

NCT04540211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

461

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Atezolizumab
DRUG: Tiragolumab
DRUG: Paclitaxel
DRUG: Cisplatin
DRUG: Atezolizumab Matching Placebo
DRUG: Tiragolumab Matching Placebo

Sponsor

Hoffmann-La Roche